{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:36:00Z","timestamp":1785332160181,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s12328-017-0726-3","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T08:06:01Z","timestamp":1488873961000},"page":"250-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adalimumab therapy in a patient with Crohn\u2019s disease with a giant pelvic paraganglioma after chemotherapy"],"prefix":"10.1007","volume":"10","author":[{"given":"Tsutomu","family":"Mizoshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Katano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tanida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Joh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,7]]},"reference":[{"key":"726_CR1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12328-012-0314-5","volume":"5","author":"T Mizoshita","year":"2012","unstructured":"Mizoshita T, Tanida S, Kusumoto S, et al. Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn\u2019s disease accompanied by chronic myeloid leukemia. Clin J Gastroenterol. 2012;5:302\u20136.","journal-title":"Clin J Gastroenterol"},{"key":"726_CR2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","volume":"40","author":"SJ Deventer Van","year":"1997","unstructured":"Van Deventer SJ. Tumour necrosis factor and Crohn\u2019s disease. Gut. 1997;40:443\u20138.","journal-title":"Gut"},{"key":"726_CR3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323\u201333 (quiz 591).","journal-title":"Gastroenterology"},{"key":"726_CR4","first-page":"396","volume":"110","author":"A Sugita","year":"2013","unstructured":"Sugita A, Koganei K, Tatsumi K, et al. Management of rectal cancer including cancer in the anal fistula with Crohn\u2019s disease. Nihon Shokakibyo Gakkai Zasshi. 2013;110:396\u2013402.","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"726_CR5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/ecco-jcc\/jjw048","volume":"10","author":"L Biancone","year":"2016","unstructured":"Biancone L, Armuzzi A, Scribano ML, et al. Inflammatory bowel disease phenotype as risk factor for cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. J Crohns Colitis. 2016;10:913\u201324.","journal-title":"J Crohns Colitis"},{"key":"726_CR6","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ijc.30183","volume":"139","author":"TR Heuvel van den","year":"2016","unstructured":"van den Heuvel TR, Wintjens DS, Jeuring SF, et al. Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer. 2016;139:1270\u201380.","journal-title":"Int J Cancer"},{"key":"726_CR7","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.mayocp.2015.03.024","volume":"90","author":"S Yadav","year":"2015","unstructured":"Yadav S, Singh S, Harmsen WS, et al. Effect of medications on risk of cancer in patients with inflammatory bowel diseases: a population-based cohort study from Olmsted County, Minnesota. Mayo Clin Proc. 2015;90:738\u201346.","journal-title":"Mayo Clin Proc"},{"key":"726_CR8","doi-asserted-by":"crossref","first-page":"R231","DOI":"10.1530\/EJE-14-0396","volume":"171","author":"EP Corssmit","year":"2014","unstructured":"Corssmit EP, Romijn JA. Clinical management of paragangliomas. Eur J Endocrinol. 2014;171:R231\u201343.","journal-title":"Eur J Endocrinol"},{"key":"726_CR9","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/eci.12495","volume":"45","author":"A Angelousi","year":"2015","unstructured":"Angelousi A, Kassi E, Zografos G, et al. Metastatic pheochromocytoma and paraganglioma. Eur J Clin Investig. 2015;45:986\u201397.","journal-title":"Eur J Clin Investig"},{"key":"726_CR10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00595-006-3291-9","volume":"36","author":"T Ito","year":"2006","unstructured":"Ito T, Imai T, Kikumori T, et al. Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result. Surg Today. 2006;36:961\u20135.","journal-title":"Surg Today"},{"key":"726_CR11","first-page":"839","volume":"8","author":"J Nurzynska-Flak","year":"2004","unstructured":"Nurzynska-Flak J, Mitura-Lesiuk M, Skomra S, et al. Second neoplasm in a 13-year-old boy complicated by Crohn\u2019s disease. Case report. Med Wieku Rozwoj. 2004;8:839\u201345.","journal-title":"Med Wieku Rozwoj"},{"key":"726_CR12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.5144\/0256-4947.2012.661","volume":"32","author":"AM Al-Gahmi","year":"2012","unstructured":"Al-Gahmi AM, Kerr IG, Zekri JM, et al. Capecitabine-induced terminal ileitis. Ann Saudi Med. 2012;32:661\u20132.","journal-title":"Ann Saudi Med"},{"key":"726_CR13","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1200\/JCO.2010.31.8899","volume":"29","author":"P Blombery","year":"2011","unstructured":"Blombery P, Prince HM, Levinson M, et al. Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma. J Clin Oncol. 2011;29:e110\u20132.","journal-title":"J Clin Oncol"},{"key":"726_CR14","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/gut.2007.139972","volume":"57","author":"D Dost","year":"2008","unstructured":"Dost D, van Leerdam ME, van Dekken H, et al. Crohn\u2019s-like enterocolitis associated with mycophenolic acid treatment. Gut. 2008;57:1330.","journal-title":"Gut"},{"key":"726_CR15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.transproceed.2012.11.003","volume":"45","author":"AD Jakes","year":"2013","unstructured":"Jakes AD, Roy A, Veerasamy M, et al. Case report: Crohn\u2019s-like mycophenolate-induced colitis, a fallout in steroid-free regimens. Transpl Proc. 2013;45:842\u20134.","journal-title":"Transpl Proc"},{"key":"726_CR16","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","volume":"9","author":"V Annese","year":"2015","unstructured":"Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9:945\u201365.","journal-title":"J Crohns Colitis"},{"key":"726_CR17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","volume":"63","author":"L Beaugerie","year":"2014","unstructured":"Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416\u201323.","journal-title":"Gut"},{"key":"726_CR18","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1097\/MIB.0b013e3182807618","volume":"19","author":"M Mason","year":"2013","unstructured":"Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis. 2013;19:1306\u201321.","journal-title":"Inflamm Bowel Dis"},{"key":"726_CR19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2013.441","volume":"109","author":"GR Lichtenstein","year":"2014","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn\u2019s disease: results from the TREAT Registry. Am J Gastroenterol. 2014;109:212\u201323.","journal-title":"Am J Gastroenterol"},{"key":"726_CR20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.12624","volume":"39","author":"CJ Williams","year":"2014","unstructured":"Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447\u201358.","journal-title":"Aliment Pharmacol Ther"},{"key":"726_CR21","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","volume":"311","author":"N Nyboe Andersen","year":"2014","unstructured":"Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311:2406\u201313.","journal-title":"JAMA"},{"key":"726_CR22","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/MIB.0000000000000741","volume":"22","author":"F Poullenot","year":"2016","unstructured":"Poullenot F, Seksik P, Beaugerie L, et al. Risk of incident cancer in inflammatory bowel disease patients starting anti-TNF therapy while having recent malignancy. Inflamm Bowel Dis. 2016;22:1362\u20139.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-017-0726-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-017-0726-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-017-0726-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T08:25:04Z","timestamp":1494663904000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-017-0726-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s12328-017-0726-3","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,7]]}}}